Description: MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.
Home Page: www.macrogenics.com
MGNX Technical Analysis
9704 Medical Center Drive
Rockville,
MD
20850
United States
Phone:
301 251 5172
Officers
| Name | Title |
|---|---|
| Dr. Scott Koenig M.D., Ph.D. | Pres, CEO & Director |
| Mr. James Karrels | Sr. VP, CFO & Corp. Sec. |
| Mr. Eric Blasius Risser | Chief Operating Officer |
| Dr. Thomas M. Spitznagel Ph.D. | Sr. VP of Technical Operations |
| Dr. Ezio Bonvini | Sr. VP of Research & Chief Scientific Officer |
| Dr. Christopher Shayne James M.D. | VP of Investor Relations & Corp. Communications |
| Mr. Jeffrey Stuart Peters | Sr. VP & Gen. Counsel |
| Dr. Stephen L. Eck M.D., Ph.D. | Sr. VP of Clinical Devel. & Chief Medical Officer |
| Ms. Lynn Cilinski | VP, Controller & Treasurer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.1198 |
| Price-to-Sales TTM: | 4.079 |
| IPO Date: | 2013-10-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 427 |